Drug Profile
Research programme: anti-infectives - AureoGen Biosciences/Takara-Bio
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Takara Bio
- Developer AureoGen Biosciences
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Mycoses
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mycoses in USA
- 01 Feb 2007 Preclinical trials in Bacterial infections in USA (unspecified route)